Erenumab
NERVOUS SYSTEM
Also known as: aimovig, AMG 334, AMG-334, erenumab (genetical recombination), erenumab-aooe
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Erenumab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2018. DrugCentral lists 1 molecular target, including RAMP1|CALCRL. Recorded indications include Migraine and Prevention of migraine attacks.
- Molecular targets: RAMP1|CALCRL (1 listed in DrugCentral).
- Indications: Migraine and Prevention of migraine attacks.
- ATC code: N02CD01 (Calcitonin gene-related peptide (CGRP) antagonists).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Migraine
- Prevention of migraine attacks
Mechanism & targets
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Calcitonin-gene-related peptide receptor | RAMP1|CALCRL | other | Ki 10.70 |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-06-23 | PMDA | — | AMGEN K.K. | |
| 2018-07-26 | EMA | — | NOVARTIS EUROPHARM LIMITED | |
| 2018-05-17 | FDA | — | AMGEN INC |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
N02CD01 | NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Accidental exposure to product | 14840.6 |
| Wrong technique in product usage process | 12302.6 |
| Device difficult to use | 11915.9 |
| Drug dose omission by device | 5791.2 |
| Product storage error | 3401.1 |
| Intercepted product administration error | 1998.8 |
| Device issue | 1919.2 |
| Incorrect dose administered by device | 1601.4 |
| Blepharospasm | 1341.6 |
| Occupational exposure to product | 1328.1 |
| Device use error | 1292.9 |
| Injection site haemorrhage | 1136.9 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1582205-90-0 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Erenumab used for?
DrugCentral lists the following indications for Erenumab: Migraine and Prevention of migraine attacks.
How does Erenumab work?
Its molecular targets in DrugCentral include RAMP1|CALCRL.
When was Erenumab first approved?
Erenumab was first approved by the FDA in 2018.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5284 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL3833329 — compound record and bioactivity
- DrugBank DB14039 — drug record
- FDA UNII I5I8VB78VT — substance identity
- DailyMed: FDA labels for Erenumab — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.